clinical trial · NCT04270058

TEGSEDI Pregnancy Surveillance Program

Akcea Therapeutics·—·not yet recruiting·n = 20

Hereditary Transthyretin-mediated Amyloidosis With PolyneropathyPregnancyinotersen

brief summary

This is a worldwide safety surveillance study of pregnancy outcomes in women with hATTR-PN who may have been exposed or were not exposed to TEGSEDI prior to or during the pregnancy and of pediatric outcomes up to 1 year of age.

started

Dec 1, 2025

primary completion

Nov 15, 2030

completion

Nov 15, 2030

last updated

Aug 19, 2025

official title

Pregnancy Surveillance Program of Women and Infants Exposed to TEGSEDI During Pregnancy

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol